A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2004
11/11/2004	US20040221855 Methods for monitoring treatment of disease
11/11/2004	DE202004009563U1 Sustained release pharmaceutical composition containing tamsulosin comprises specific dissolution profile ensuring high activity without side-effects, useful for treating urinary disorders such as benign prostate hyperplasia
11/11/2004	DE19718245C5 Synthetische Triglyceride auf Basis konjugierter Linolsäure, Verfahren zu deren Herstellung und deren Verwendung Synthetic triglycerides based on conjugated linoleic acid, processes for their preparation and their use
11/11/2004	DE10317109A1 Zubereitungen zur oralen Aufnahme Preparations for oral administration
11/11/2004	DE10317108A1 Transdermal applizierbares Beruhigungs- und Sedierungsmittel Transdermally administrable sedatives and Sedierungsmittel
11/11/2004	DE10317023A1 Oral dosage form useful in the treatment and prevention of gastrointestinal disorders e.g. inflammatory disorders and lesions such as gastric ulcer comprises proton pump inhibitor and basic excipients
11/11/2004	DE10316087A1 Stabilizing polymorphic forms of fluvastatin sodium in solid medicaments, for use as HMG-CoA reductase inhibiting cardiovascular drugs, by adjusting water content and water activity values
11/11/2004	DE10257824B4 Zusammensetzung zur Schmerzbehandlung, insbesondere zur Behandlung von Gelenkschmerzen Composition for the treatment of pain, particularly for the treatment of joint pain
11/11/2004	CA2847543A1 Annatto extract compositions, including geranyl geraniols and methods of use
11/11/2004	CA2670067A1 Treatment of incontinence
11/11/2004	CA2536964A1 C-fms kinase inhibitors
11/11/2004	CA2533074A1 Regulation of guanine nucleotide exchange factor
11/11/2004	CA2524457A1 Process fot the preparation of (4-hydroxy-6-oxo-tetrahydropyran-2-yl) acetonitrile and derivatives thereof
11/11/2004	CA2524251A1 Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders
11/11/2004	CA2524248A1 Angiotensin ii receptor blockers for preventing the development or progression of microvascular disease due to diabetes
11/11/2004	CA2524245A1 The use of azetidinecarboxamide derivatives in therapy
11/11/2004	CA2524241A1 Extended release venlafaxine tablet formulation
11/11/2004	CA2524175A1 Sugar intake-ability enhancer
11/11/2004	CA2524165A1 Selective testicular 11.beta.-hsd inhibitors and methods of use thereof
11/11/2004	CA2524134A1 Adiponectin production enhancer
11/11/2004	CA2524125A1 Antibiotic tetrahydro-.beta.-carboline derivatives
11/11/2004	CA2524071A1 Toll-like receptor 9 effector agents and uses thereof
11/11/2004	CA2523868A1 Combinations comprising a protein tyrosine kinase receptor antagonist and a chemotherapeutic or naturally occurring, semi-synthetic of synthetic therapeutic agent for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
11/11/2004	CA2523852A1 Use of tyrosine kinase inhibitors for treating cerebral ischemia
11/11/2004	CA2523830A1 Methods and compositions using gonadotropin hormone releasing hormone
11/11/2004	CA2523600A1 Methods utilising g-protein coupled receptor 54
11/11/2004	CA2523577A1 Methods for treating interleukin-6 related diseases
11/11/2004	CA2523576A1 Preventives or remedies for hepatopathy
11/11/2004	CA2523573A1 Methods for reducing or preventing transmission of nosocomial pathogens in a health care facility
11/11/2004	CA2523567A1 Method for promoting uninterrupted sleep by administration of trospium chloride
11/11/2004	CA2523565A1 Prophylactic pretreatment with antioxidants
11/11/2004	CA2523541A1 Novel ketolide derivatives
11/11/2004	CA2523517A1 Bcl2l12 polypeptide activators and inhibitors
11/11/2004	CA2523426A1 Aza spiro alkane derivatives as inhibitors of metalloproteases
11/11/2004	CA2523363A1 Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
11/11/2004	CA2523339A1 Agent for preventing and healing constipation
11/11/2004	CA2523331A1 Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse
11/11/2004	CA2523266A1 Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
11/11/2004	CA2523152A1 Use of irinotecan for treatment of resistant breast cancer
11/11/2004	CA2523151A1 Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
11/11/2004	CA2523102A1 Substituted indoline and indole derivatives
11/11/2004	CA2523083A1 Antiviral phosphonate analogs
11/11/2004	CA2523025A1 Spex compositions and methods of use
11/11/2004	CA2523021A1 Improved extraction and purification method for cereal beta-glucan
11/11/2004	CA2522977A1 Immunomodulator phosphonate conjugates
11/11/2004	CA2522971A1 Method of improved diuresis in individuals with impaired renal function
11/11/2004	CA2522845A1 Kinase inhibitor phosphonate conjugates
11/11/2004	CA2522739A1 Pharmaceutical compositions comprising cereal beta (1-3) beta (1-4) glucan
11/11/2004	CA2522708A1 Compositions for affecting weight loss
11/11/2004	CA2522431A1 Inhibitors of akt activity
11/11/2004	CA2522430A1 Inhibitors of akt activity
11/11/2004	CA2522262A1 Inhibitors of akt activity
11/11/2004	CA2522089A1 Prevention of hiv-1 infection by inhibition of rho-mediated reorganization and/or content alteration of cell membrane raft domains
11/11/2004	CA2522043A1 Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage
11/11/2004	CA2521938A1 9-azabicyclo[3.3.1]non-6-ene derivatives with a heteroatom at the 3-position as renin inhibitors
11/11/2004	CA2521924A1 Azabicyclononene derivatives
11/11/2004	CA2521898A1 Diazabicyclononene derivatives
11/11/2004	CA2521735A1 Fast dissolving orally consumable films containing a sucralose as a sweetener
11/11/2004	CA2521624A1 Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
11/11/2004	CA2521152A1 Use of a topical medicament comprising riluzole
11/11/2004	CA2521149A1 Annatto extract compositions, including geranyl geraniols and methods of use
11/11/2004	CA2520842A1 Cannabinoid receptor ligands and uses thereof
11/11/2004	CA2520779A1 Agent for intra-airway administration
11/11/2004	CA2519840A1 Anti-cancer phosphonate analogs
11/11/2004	CA2501694A1 Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the same
11/10/2004	EP1475639A2 Tumour-specific P450 protein
11/10/2004	EP1475440A2 Growth differentiation factor-3
11/10/2004	EP1475386A2 Steroid nitrates for the treatment of oxidative injury and endothelial dysfunction
11/10/2004	EP1475382A1 Compounds as semaphorin inhibitors
11/10/2004	EP1475378A1 Antidiabetic thiazolidinedione potassium salt
11/10/2004	EP1475377A1 Derivatives of indole and their use as phosphodiesterase 4 inhibitors
11/10/2004	EP1475376A1 Hair composition containing a pyrimidine-n-oxide derivative and its use to stimulate keratinic fiberes growth and/or preventing their loss
11/10/2004	EP1475371A1 1-substituted-1-aminomethyl-cycloalkane derivatives (= gabapentin analogues), their preparation and their use in the treatment of neurological disorders
11/10/2004	EP1475363A1 Method for stabilizing reduced coenzyme q 10 and composition therefor
11/10/2004	EP1475105A1 Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
11/10/2004	EP1475103A1 Remedies for chronic kidney diseases
11/10/2004	EP1475102A1 Remedy for hypertension
11/10/2004	EP1475099A1 Use of botulinum toxin to treat urinary incontinence
11/10/2004	EP1475095A1 Percutaneous preparations
11/10/2004	EP1475094A1 Pyrazolo[4,3-D]pyrimidines, process for their preparation and methods of use
11/10/2004	EP1475093A1 Micronized Zolpidem hemitartrate
11/10/2004	EP1475091A1 Mycophenolate mofetil - high dose oral suspensions
11/10/2004	EP1475090A1 Drugs for mitochondrial diseases
11/10/2004	EP1475089A1 Process for producing granules containing branched amino acids
11/10/2004	EP1475088A1 Use of kynurenine-3-hydroxylase inhibitors for the preparation of medicaments for the treatment of l-dopa induced movement disorders, dyskinesias, drug addiction, pain and cataract
11/10/2004	EP1475087A2 A method for chemoprevention of prostate cancer
11/10/2004	EP1475086A2 Sibutramine metabolites
11/10/2004	EP1475085A1 Controlled-release formulations coated with aqueous dispersions of ethylcellulose
11/10/2004	EP1475083A1 Method for producing an active ingredient concentrate, and active ingredient concentrate
11/10/2004	EP1475080A2 Cosmetic composition for the treatment of skin ageing and/or stressed skin
11/10/2004	EP1474998A1 Composition useful for weight control
11/10/2004	EP1474991A1 Ubiquinol-enriched fat-containing foods
11/10/2004	EP1474687A2 Marks as modifiers of the p53 pathway and methods of use
11/10/2004	EP1474535A2 Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
11/10/2004	EP1474448A1 Rrp sequences and knockout mice and uses thereof
11/10/2004	EP1474442A2 Cytotoxic t-cell epitopes from chlamydia
11/10/2004	EP1474441A1 Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of ns3 (hepatitis c)
11/10/2004	EP1474440A2 Coniosulphides and their derivatives, method for their production and use as medicaments
11/10/2004	EP1474437A2 Improved method for obtaining betulinic acid
11/10/2004	EP1474431A2 Macrolide antibacterial compounds

1 ... 4896 4897 4898 4899 4900 4901 4902 4903 4904 4905 4906 4907 4908 4909 4910 4911 4912 4913 4914 4915 4916 ... 7860